SynthesisClinical neuroradiology2026
Endovascular Treatment of Hydrocephalus: A Systematic Literature Review.
Synthesis in Clinical neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHydrocephalus is traditionally managed with ventriculoperitoneal shunting (VPS), which is associated with high rates of infection, mechanical failure, and surgical revisions. Recent innovations in endovascular techniques have led to the development of minimally invasive cerebrospinal fluid (CSF) diversion techniques. This literature review systematically examines the development, procedural techniques, efficacy, and safety profile of endovascular treatments for communicating hydrocephalus.
methodsA systematic search was conducted in PubMed/MEDLINE, Embase, Scopus and clinicaltrials.gov from inception until March 15, 2025, following the PRISMA guidelines (PROSPERO registration number: CRD420251012455). Two reviewers independently screened and extracted data. Results are summarized descriptively.
resultsOf 5319 records identified, 16 studies were included. Of those, six were published as original articles and 10 as conference abstracts. Overall, two technical reports of endovascular treatment of hydrocephalus were found: eShunt® (n = 14 studies) and choroidal artery embolization (n = 1 studies). Outcome data are available for 70 patients treated with the eShunt®. In patients with idiopathic normal pressure hydrocephalus treated with eShunt® implantation, the Timed Up and Go test improved by 35.7%, Montreal Cognitive Assessment scores by +1.6 points, and neurogenic bladder symptom scores by -3.6s at one year. No device-related serious adverse events were reported. DISCUSSION: Endovascular CSF diversion represents an emerging, minimally invasive alternative to traditional shunting techniques for communicating hydrocephalus. While early results demonstrate technical feasibility and encouraging safety profiles, long-term data from ongoing clinical trials are critical to establish its role in standard neurosurgical and neurointerventional practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.